German Health Minister Nina Warken has ruled out any concessions to the United States regarding domestic pharmaceutical pricing, signaling a refusal to back down in a widening trade dispute.
Warken stated there is no room for compromise, pointing to existing tariff agreements as the framework for the standoff.
The minister's comments mark a significant escalation in tensions between Berlin and Washington.
The United States has launched a formal investigation into Germany's healthcare reimbursement system, accusing the country of systematically underpaying for innovative medicines.
US officials argue that these pricing controls distort market dynamics and disadvantage American drug manufacturers.
This diplomatic friction poses a tangible risk to the European pharmaceutical sector.